glp-1 startups Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 The GLP-1 War: Insights into

And the longer it takes to get pregnant, the harder it gets to maintain the benefits of being on the GLP-1

Christopher K Rayner, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia

9 Approved in 2005, exenatide was the first GLP-1 drug to be made available, and later modifications allowed for its extended release

DPP-4i have been associated with a reduction in atherosclerosis and inflammation in several studies utilizing animal models [78,79,80]

Recently, agonists of glucagon-like peptide-1 (GLP-1) receptor, designed based on the gut hormone GLP-1, have been developed as anti-obesity drugs and have demonstrated remarkable efficacy in treating both obesity and diabetes

However, how context-dependent molecular networks contribute to limit tissue damage, promote repair and, ultimately, longevity remains unclear